Overview
TerrAscend Q2 revenue misses analyst expectations, totaling $65 mln, per LSEG data
Company exits Michigan market to reduce debt and focus on core markets
Co completes $79 mln refinancing, secures additional $35 mln term loan for M&A
Outlook
TerrAscend plans to use $35 mln for strategic M&A
TerrAscend aims for improved profitability in New Jersey, Maryland, Pennsylvania
Company sees potential adult-use cannabis sales in Pennsylvania
Result Drivers
MICHIGAN EXIT - Co exits Michigan market to reduce debt and focus on core markets
NORTHEAST MARKETS - Strong performance in New Jersey, Maryland, and Pennsylvania drives results
PRICE COMPRESSION - Retail revenue increase offset by price compression in New Jersey
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$65 mln
$67.90 mln (3 Analysts)
Q2 Gross Margin
51.1%
Q2 Adjusted EBITDA from Cont. Ops
$16 mln
Q2 Free Cash Flow
$5 mln
Q2 Gross Profit
$33.20 mln
Q2 Net Income from Cont. Ops
-$6.40 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Terrascend Corp is C$1.88, about 64.8% above its August 6 closing price of C$0.66
Press Release: ID:nGNX3fn0KT
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)